All trials View full record on ClinicalTrials.gov
NCT05469360PHASE1RECRUITING
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
✨ Plain-English version on the way · ~2 days
We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)Read full record on ClinicalTrials.gov
Eligibility check — Phoenix members
Phoenix members see for THIS trial:
- APOE genotype match
- Cognitive status fits inclusion
- Specific exclusions flagged
- Distance to nearest site
Sites
10 locations
Start
2023-02-23
Interventions tested
- DRUGNIO752
- DRUGNIO752
- DRUGMatching placebo
- DRUGNIO752
- DRUGNIO752
- DRUGNIO752
- DRUGMatching placebo